Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein

Journal of Peptide Science

Volumn 15, Issue 4, 2009, Pages 319-325

  Joseph, Leroy C ^a   Bennett, James A ^a   Kirschner, Karl N ^b,c   Shields, George C ^b   Hughes, John ^a   Lostritto, Nicole ^a   Jacobsona, Herbert I ^a   Andersen, Thomas T ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b HAMILTON COLLEGE   (United States)

^c FRAUNHOFER IAIS   (Germany)

Author keywords

Alpha fetoprotein; Anticancer; Breast cancer; Dose range; Linear peptides

Indexed keywords

ALPHA FETOPROTEIN; GLUTAMYLLYSYLTHREONYLHYDROXYPROLINYLVALYLHYDROXYPROLINYLGLYCYLASPARAGINE; NONAPEPTIDE; OLIGOPEPTIDE; THREONYLHYDROXYPROLINYLVALYLASPARAGINE; THREONYLHYDROXYPROLINYLVALYLASPARAGINYLHYDROXYPROLINYLGLYCYLASPARAGINYLGLUTAMYLLYSINE; UNCLASSIFIED DRUG; AFP PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; PEPTIDE FRAGMENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIESTROGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PURIFICATION; RAT; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; FEMALE; GROWTH, DEVELOPMENT AND AGING; SYNTHESIS; TUMOR CELL LINE; UTERUS; XENOGRAFT;

MUS; RATTUS;

ALPHA-FETOPROTEINS; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MICE; PEPTIDE FRAGMENTS; TRANSPLANTATION, HETEROLOGOUS; UTERUS;

EID: 65349144842     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1119     Document Type: Article

References (19)

1. Andersen TT, Georgekutty J, DeFreest LA, Amaratunga G, Narendran A, Lemanski N, Jacobson HI, Bennett JA. An alpha-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen. Br. J. Cancer 2007; 97: 327-333.
2. Bennett JA, Defreest L, Anaka I, Saadati H, Balulad S, Jacobson HI, Andersen TT. AFPep: an anti-breast cancer peptide that is orally active. Breast Cancer Res. Treat. 2006; 98: 133-141.
3. Parikh RR, Gildener-Leapman N, Narendran A, Lin HY, Lemanski N, Bennett JA, Jacobson HI, Andersen TT. Prevention of N-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP. Clin. Cancer Res. 2005; 11: 8512-8520.
4. De Freest LA, Mesfin FB, Joseph L, McLeod DJ, Stallmer A, Reddy S, Balulad SS, Jacobson HI, Andersen TT, Bennett JA. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization. J. Pept. Res. 2004; 63: 409-419.
5. Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI. A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc. Natl. Acad. Sci. U.S.A. 2002; 99: 2211-2215.
6. Mesfin FB, Bennett JA, Jacobson HI, Zhu S, Andersen TT. Alpha-fetoprotein-derived antiestrotrophic octapeptide. Biochim. Biophys. Acta 2000; 1501: 33-43.
7. Mesfin FB, Andersen TT, Jacobson HI, Zhu S, Bennett JA. Development of a synthetic cyclized peptide derived from alpha-fetoprotein that prevents the growth of human breast cancer. J. Pept. Res. 2001; 58: 246-256.
8. Kirschner KN, Lexa KW, Salisburg AM, Alser KA, Joseph L, Andersen TT, Bennett JA, Jacobson HI, Shields GC. Computational design and experimental discovery of an antiestrogenic peptide derived from alpha-fetoprotein. J. Am. Chem. Soc. 2007; 129: 6263-6268.
9. Lexa KW, Alser KA, Salisburg AM. The search for low energy conformational families of small peptides: Searching for active conformations of small peptides in the absence of a known receptor. Int. J. Quantum Chem. 2007; 107: 3001-3012.
10. Kates SA, Daniels SB, Albericio F. Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides. Anal. Biochem. 1993; 212: 303-310.
11. Flouzat C, Croizet F, PerceboisM, Monteil A, Combourieu M. Solid-phase synthesis of "Head-to-Side Chain" cyclic tripeptides using allyl deprotection. Tetrahedron Lett. 1992; 38: 1191-1194.
12. Zhang Y, Kennan AJ. Efficient introduction of protected guanidines in BOC solid phase peptide synthesis. Org. Lett. 2001; 3: 2341-2344.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65: 55-63.
14. Jacobson HI, Bennett JA, Mizejewski GJ. Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res. 1990; 50: 415-420.
15. Villacampa MJ, Moro R, Naval J, Failly-Crepin C, Lampreave F, Uriel J. Alpha-fetoprotein receptors in a human breast cancer cell line. Biochem. Biophys. Res. Commun. 1984; 122: 1322-1327.
16. Naval J, Villacampa MJ, Goguel AF, Uriel J. Cell-type-specific receptors for alpha-fetoprotein in a mouse T-lymphoma cell line. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 3301-3305.
17. Torres JM, Geuskens M, Uriel J. Receptor-mediated endocytosis and recycling of alpha-fetoprotein in human B-lymphoma and T-leukemia cells. Int. J. Cancer 1991; 47: 110-117.
18. Atemenzem A, Mbemba E, Marfaing R, Vaysse J, Pontet M, Saffar L, Charnaux N, Gattegno L. Human alpha-fetoprotein binds primary macrophages. Biochem. Biophys. Res. Commun. 2002; 296: 507-514.
19. Suzuki Y, Zeng CQY, Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. J. Clin. Invest. 1992; 90: 1530-1536.